GPCM
FBIO icon

Granite Point Capital Management’s Fortress Biotech FBIO Stock Holding History

Granite Point Capital Management’s Portfolio FBIO Stock Details FBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-31,989
Closed -$768K – 105
2018
Q3 		$768K Sell
31,989
-11
-0% -$352 0.05% 90
2018
Q2 		$1.43M Buy
+32,000
New +$1.8M 0.13% 56

Other funds holding FBIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HAG
HighPoint Advisor Group Downers Grove, Illinois $2.84B AUM 31.94% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
OPPM
Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Granite Point Capital Management's FBIO Position: Q4 2018 in Review

Granite Point Capital Management sold out of Fortress Biotech (FBIO) in Q4 2018, closing a stake of 31,989 shares — an estimated $768K sold.

Granite Point Capital Management first reported a position in FBIO in Q2 2018 and held it in 2 quarters. The position peaked at $1.43M in Q2 2018. 61 funds tracked by Wall St. Rank hold FBIO as of Q4 2018.

  • Granite Point Capital Management reported no remaining Fortress Biotech position as of Q4 2018 after selling out during the quarter.
  • Granite Point Capital Management sold 31,989 Fortress Biotech shares in Q4 2018, an estimated $768K.
  • Granite Point Capital Management first reported a position in Fortress Biotech in Q2 2018 and held it in 2 quarters.
  • Granite Point Capital Management's Fortress Biotech position peaked at $1.43M in Q2 2018.
  • 61 funds tracked by Wall St. Rank held Fortress Biotech as of Q4 2018.

Based on Granite Point Capital Management's 13F filing for Q4 2018, filed 5 Feb 2019.